Figure 16.

DNA mutational analysis of CTCs isolated by NanoVelcro Chips. a) A workflow summarizing EGFR mutation detection starting from NSCLC CTC purification via thermoresponsive NanoVelcro system, followed by WGA, PCR and quality control, to Sanger sequencing. b) Monitoring evolution of hotspot mutations in EGFR gene through serial CTC analysis with concurrent CT images for an index NSCLC patient at timepoints I) before gefitinib (first-generation EGFR inhibitor) treatment, II) 3 months post-treatment, and III) tumor relapse because of resistance to gefitinib. Before gefitinib treatment, L858R mutation was detected in both CTCs and tumor tissues. After the initiation of gefitinib, tumor regression was observed. T790M mutation, but not L858R mutation, was detected at the time of radiographic progression. a and b) Reproduced with permission.^[120] Copyright 2018, Elsevier. c) WGS on single prostate cancer CTCs isolated by PN-NanoVelcro/LCM assay revealed that SNVs and gene rearrangements in tumor suppressor genes including RB1, BRCA2, and PTEN were shared by CTCs and tumor tissues, but not by WBCs. Reproduced under the terms of the CC-BY License.^[233] Copyright 2015, Jiang et al. Published by Oncotarget.